Identifying new compounds for Chagas disease
What is it about?
In this project we developed a Pathway Genome Databse for T. Cruzi which is publically accessible. We used published data from the Broad Institute to build machine learning models to predict additional compounds. We bough and test ed compounds in vitro. Some of the most active were tested in vivo. Pyronaridine was found to have 85% efficacy in the mouse model of disease.
Why is it important?
There is no FDA approved drug for Chagas Disease and its becoming a major issue in the south of the USA as well as in South America. Pyronaridine is approved in Europe as an antimalarial and may have a faster rout to the clinic.
The following have contributed to this page: Dr Sean Ekins